Perrigo Company plc Restructuring and Related Cost, Accelerated Depreciation
Perrigo Company plc (PRGO) reported Restructuring and Related Cost, Accelerated Depreciation of $15.40 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveAcceleratedDepreciation · last filed 2026-08-05
- Perrigo Company plc restructuring and related cost, accelerated depreciation for the quarter ending 2026-06-27 was $15.40M, a 242.22% increase year-over-year.
- Perrigo Company plc restructuring and related cost, accelerated depreciation for the quarter ending 2026-03-28 was $3.50M.
- Perrigo Company plc restructuring and related cost, accelerated depreciation for the quarter ending 2025-06-28 was $4.50M.
| Period end | Restructuring and Related Cost, Accelerated Depreciation 3 month | Restructuring and Related Cost, Accelerated Depreciation 6 month |
|---|---|---|
| 2026-06-27 | $15.40M 10-Q · filed 2026-08-05 | $18.90M 10-Q · filed 2026-08-05 |
| 2026-03-28 | $3.50M 10-Q · filed 2026-05-06 | |
| 2025-06-28 | $4.50M 10-Q · filed 2026-08-05 | $4.50M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |